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Abstract
Background: Denture-associated stomatitis is a chronic infection of the oral cav-
ity that may be associated with a number of bacterial and candidal organisms as 
well as some predisposing factors. Its management may prove to be difficult if the 
treatment plan was not comprehensive in addressing all the factors involved in its 
etiology. The aim of this review is to underline the effectiveness of antifungal drugs 
in the management of denture-associated stomatitis according to our personal 
experience and the recently published literature.
Methods: Articles were obtained from pubmed as well as by a hand search. 
Denture stomatitis and antifungal were used as keywords. Only articles written 
in English and which were published starting from the year 1990 were included.
Conclusions: Antifungal drugs certainly have a place in the management of 
denture-associated stomatitis. However, their use should be called upon after the 
control of factors known to cause this infection. Denture and oral hygiene, and 
management of adverse medical conditions should be the primary goal of treat-
ment. This should go hand in hand with the application of topical antifungal agents 
particularly those in the cream or gel form for better patients’ compliance. 
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Introduction
Denture-associated stomatitis (DAS) (Candida-associated 
denture stomatitis, chronic atrophic candidiasis, denture-sore 
mouth) is a chronic infection of the oral mucosa caused solely 
by Candida species or in association with bacteria (1). The role 
of Candida, and specifically C. albicans, in development of 
denture stomatitis is associated with pathogenic overgrowth 
of Candida on denture surfaces and the oral mucosa, and is 
widely accepted as a leading etiological factor.
It affects 24-60% of denture wearers (2), and it is usually 
found on the palatal mucosa beneath the fitting surface of 
the upper denture. Dental prostheses may produce a local 
environment of lowered pH and anaerobic conditions by de-
creasing the flow of oxygen and saliva to the underlying tissue; 
these conditions favor fungal overgrowth (3-5). Furthermore, 
biofilms in denture plaque represent a protective reservoir for 
oral microbes (6). It has also been demonstrated that Candida 
organisms have an affinity for the tissue side of the denture 
and although Candida infection is the primary aetiology of 
most of these lesions, other factors such as poor denture 
hygiene and associated bacterial flora, continuous denture 
wearing, ill-fitting and traumatic dentures, carbohydrate-rich 
diet and rarely, allergy to denture material are contributory 
co-factors (7). It was noticed that the prevalence is associated 
with the amount of tissue covered by dentures (2). It was 
also found that wearing denture at night and smoking were 
associated with the most extensive inflammation (8).
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There is chronic erythema and edema of the mucosa in con-
tact with the fitting surface of the denture which is usually 
the maxillary denture. However, mucosa under mandibular 
dentures is hardly ever involved being protected by salivary 
flow (1). Clinically, there are three subtypes of DAS; type I is 
a localized simple inflammation or pinpoint hyperemia, type 
II is an erythematous or generalized simple type presenting 
as more diffuse erythema involving a part of or the entire 
denture-covered mucosa, and type III is a granular or papil-
lary type commonly involving the central part of the hard 
palate and alveolar ridge (Inflammatory Papillary hyperplasia). 
All three types can be found simultaneously and in varying 
combinations. (2) Although the lesion is not painful, it might 
cause some unfavorable complications. The affected mucosa 
is atrophic providing less support for the dentures. Some pa-
tients complain of burning sensation or tingling sensation be-
neath the denture. Patients may also complain of associated 
angular cheilitis (1). Early reports pointed to the carcinogenic 
potential of candidal infections (9). In some patients with 
HIV infection, oral candidiasis may also lead to secondary 
complications such as esophageal candidiasis.(1)
Management of DAS depends upon a compehensive treat-
ment plan. Elimination of predisposing factors is considered 
the first and most crucial step. The use of topical and systemic 
antifungal drugs is also considered an important measure. 
The goals of treatment are to identify and eliminate pos-
sible contributing factors, prevent systemic dissemination and 
eliminate any associated discomfort (10).
The aim of this paper is to discuss the management of DAS 
with special emphasis on antifungal drugs, a rapidly develop-
ing field for the treatment of this infection as well as other 
types of oral candidiasis. 
Antifungal therapy of  
denture-associated stomatitis
Antifungal agents are either polyenes (nystatin and am-
photericin B) or azoles which are classified into: imidazoles( 
clotrimazole, econazole, fenticonazole, isoconazole, ketocon-
azole, miconazole, sulconazole, tioconazole); and triazoles 
(fluconazole, itraconazole) (1). Some of these drugs are used 
topically, while others are used in a systemic form. Recent re-
search has concentrated upon a number of antifungal drugs 
for the treatment of DAS namely, fluconazole, itraconazole, 
miconazole and nystatin. 
Topical Antifungals
Topical antifungal therapy for oral candidal infections is avail-
able in many forms like pastilles, troches, creams, ointments 
and oral suspensions and remains the cornerstone of treat-
ment in mild, localized cases of candidoses in healthy patients 
(10).
It was shown that most Candida species are susceptible to 
topical antifungal drugs like amphotericin B, (11, 12) nystatin 
(13), Miconazole (14-17) and clotrimazole (1). Being recom-
mended as the first choice of treatment, (1) Amphotericin B 
is usually in the form of lozenges or oral suspension, while 
nystatin can be in the form of cream, pastille and oral sus-
pension. On the other hand, clotrimazole is usually presented 
in a cream or solution form; the cream form also has an 
antistaphylococcal activity (1). Miconazole can be used as a 
lacquer (15, 18), gel (12, 17) or cream. The gel form of mi-
conazole was shown to be more effective than the lacquer 
form (17). Chlorhexidine in the form of mouth wash (0.2%) 
and 2% suspension for overnight denture disinfection, can 
also be used to supplement antifungal drugs (19).
Systemic antifungals
Systemic antifungal agents have been recommended for pa-
tients with poor compliance such as patients with special 
needs. They are also recommended for immunocompromised 
patients (20). Among systemic antifungal drugs, fluconazole 
and itraconazole have been the most extensively studied and 
proven as efficient antifungal drugs (21,22). Specifically, flu-
conazole is one of the most effective agents for the treat-
ment of oropharyngeal candidiasis in HIV-infected patients 
as well as prophylaxis for fungal infections in neutropenic 
patients undergoing bone marrow transplantation (23,24). 
It was shown to be effective, especially when administered 
with an oral antiseptic such as chlorhexidine.(25) Compared 
to miconazole, it was demonstrated that fluconazole is more 
effective (16). It is the drug of choice in the management of 
HIV-related oral candidiasis and it is superior to other topi-
cally administered or systemic antifungals due to its water-
solubility, oral bioavailability and good safety profile (26). 
Fluconazole is usually used in the form of 50 or 100 mg 
capsules. However, it should be given with caution in certain 
circumstances as it interacts with anticoagulants among other 
drugs. It is also contraindicated in pregnancy and liver and 
renal disease. Itraconazole also was shown to be effective 
in the management of DAS, (22) and even more effective 
than fluconazole (21). Martin-Mazuelos et al., (1997) showed 
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that itraconazole was effective against 100% of fluconazole-
resistant strains (27). Similar to fluconazole, it is usually used 
in the form of 100 mg capsules.
Discussion
The field of antifungal therapy is rapidly developing, espe-
cially that there is a better understanding of the pathogen-
esis of disease and the worldwide problem of antimicrobial 
resistance. The multifaceted nature of DAS etiology involves 
numerous predisposing factors operating locally and systemi-
cally. Consequently, treatment plan should address all pos-
sible etiological factors before the decision on the antifungal 
drug is made. Denture and oral hygiene were found to be 
of primary importance in healing of lesions and preventing 
its recurrence (28).
This is to improve prognosis and to prevent the recurrence 
of infection (29,30). Denture cleaning plays an important role 
in eliminating the conditions that favor candidal growth. This 
can be achieved by mechanical means, such as ultrasonic 
cleaners, or chemical cleansers which are particularly of ben-
efit for institutionalized elders or patients who are unable 
to maintain a proper level of oral hygiene due to mental or 
physical disability.
Antifungal drugs should be used alongside denture care. 
However, and despite the availability of a number of antifun-
gal drugs, therapeutic failure is not uncommon. This is in part 
due to the diluent effect of saliva and cleansing action of the 
oral musculature which often tend to reduce the availability 
of the antifungal drug below the effective therapeutic con-
centration. Another cause of failure is the presence of Can-
dida biofilms on mucosal and inert surfaces like prostheses 
and implants. In response to attachment to a surface, fungal 
cells produce biofilms, three-dimensional structures made up 
of cells surrounded by exo-polymeric, mostly polysaccharide 
matrices that contribute to the infectious process and anti-
biotic resistance (31). Biofilms are difficult to eliminate and 
are a source of many refractory infections (28). It was shown 
that development of antifungal resistance was associated 
with increased pathogenicity in systemic infection as well as 
increased propensity for biofilm formation (32). Furthermore, 
the use of topical antifungals may be associated with lower 
patient compliance because it is required from the patient to 
use multiple daily doses for a relatively long period of time 
that may extend to three or four weeks (33). Poor patient 
compliance coupled with possible underlying immunodefi-
ciency and emergence of drug resistance are all additional 
factors against complete recovery, leading to chronic recur-
rences of the disease (1). Another factor that would affect 
prognosis of this infection is its severity. Mild and moderate 
types are usually more responsive to antimicrobial therapy 
than the severe type which usually requires systemic antifun-
gals and may need additional surgical treatment to achieve 
a better prognosis (18).
Other factors that may complicate treatment is the systemic 
condition of the patient that plays an important role in modi-
fying the immune response to different sorts of infections. 
Medical problems can complicate local infections particulary 
in immunocompromised patients (28), Diabetes (34), and HIV 
infection (35), for instance, present a problem when treating 
oral Candidal infections. 
Smoking is considered an important factor in modulating 
the response of oral mucosa to the different factors (36), 
however, this relationship was not confirmed in the case of 
DAS (37). 
Pharmacologic treatment should be tailored to the individual 
patient, based on his/her health status and the clinical pre-
sentation and severity of infection. Leaving dentures out at 
night and improvement of denture hygiene should be the 
primary therapeutic approach, prior to instituting antifungal 
therapy. 
Antifungal drugs certainly have a place in treating DAS. In 
healthy patients, the antifungal drugs of choice would be 
a topical polyene drug. However, if the patient is immuno-
compromised, the need to a systemic antifungal drug like 
fluconazole may arise. It was shown that fluconazole inhibits 
biofilm formation by both fluconazole-susceptible and fluco-
nazole-resistant Candida albicans strains (38). Patient educa-
tion regarding denture hygiene, the number of daily doses 
and duration of therapy is important. Another important 
aspect is the follow-up of patient’s condition to determine 
the response to treatment. Failure of treatment may neces-
sitate culture and susceptibility testing together with further 
investigating the patient’s medical condition. Some studies 
have shown that some C. glabrata strains are developing re-
sistance to fluconzole and were detected in association with 
denture-related stomatitis and among patients treated in in-
tensive care units (12, 39). Previous fluconazole use has also 
been identified as a significant risk factor for development of 
fluconazole-resistant among non-albicans Candida species, 
especially Candida glabrata and Candida krusei ( 39 ). There-
fore, there is a need to identify patients at risk of developing 
candidasis caused by species resistant to fluconazole in order 
to initiate adequate empirical antifungal therapy. 
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